RE:RE:RE:RE:RE:RE:RE:RE:RE:didn't take it all in...but In 2015 there were 74,000 new cases of bladder cancer in the US.
Approximately 70% of bladder cancer cases are classified as NMIBC or 51,800 cases.
Of these NMIBC cases approximately 40% or 20,720 will fail BCG therapy.
Of these cases approximately 75% or 15,540 will fail a "re-challenge" with BCG therapy.
If the Theralase treatment proves effective for NMIBC, about 15,000 American patients a year will be able to benefit as soon as the treatment has FDA approval.
Over time Theralase may be considered as an alternative for the BCG therapy itself and may also be used against MIBC and so may be able to help all 74,000 patients once approval for this is granted.
Other cancer indication trials are also in the works.
bencro wrote: Woundedknee ... In the Oct. 2015 AGM video, as Langosta reminded this board, Dr. Kulkarni clearly describes the "
last resort scenario" of NMIBC current options and explains why our technology is so welcomed.
Go watch starting
@05:22+ where Dr. Kulkarni mentions "
What do you do if BCG fails again?". He then goes through to mention the last resort scenario (cystectomy) and where our technology would be more than welcome.
So HC is allowing us to enter at this "last resort scenario" window. Otherwise, what would be Dr. Kulkarni's interest to talk about that specific segment then???
Authorities will then analyze how compelling our data is to advise on more, and that's why efficacy exploratory endpoint is allowed.
Photodynamic Cancer Therapy Update - AGM Oct 2, 2015